Revaia secures €40M to double down on Hublo
European growth equity investor Revaia has closed a €40 million reinvestment vehicle linked to its planned 2025 exit from French workforce management scale-up Hublo. The new vehicle allows existing and new limited partners to maintain or increase exposure to the high-growth health and HR technology company beyond the initial fund’s lifecycle.
Structure of the reinvestment vehicle
The dedicated vehicle is designed as a continuation fund, a structure that has become increasingly common in the venture capital and growth equity ecosystem as managers seek to hold on to top-performing assets for longer. By carving out the position in Hublo into a separate pool of capital, Revaia can provide liquidity to its original fund investors while offering fresh capital partners extended upside.
Market observers note that such structures are typically used when a portfolio company has clear visibility on future revenue growth, profitability and potential strategic interest, but where the original fund is approaching the end of its term.
Hublo and the digitalisation of healthcare staffing
Hublo operates a digital platform that streamlines workforce planning, shift allocation and compliance for hospitals, clinics and care homes. By automating scheduling and onboarding, the company aims to reduce reliance on manual processes and temporary agencies, a critical issue for European healthcare systems facing chronic staff shortages.
The company’s tools leverage cloud-based software and data-driven dashboards to give HR teams real-time visibility into staffing gaps and overtime, while providing healthcare professionals with mobile access to shifts and contracts.
Signal for European growth equity
The successful closing of the €40 million vehicle underscores continued investor demand for mature European scale-ups with resilient business models. Despite a more cautious funding environment, secondary and continuation structures are enabling managers such as Revaia to return capital to LPs while still backing category leaders.
For Hublo, the move provides a stable shareholder base ahead of its anticipated 2025 liquidity event, whether via strategic sale or broader secondary transaction, and supports ongoing expansion across key European healthcare markets.